129 results
8-K
EX-99.1
BFRI
Biofrontera Inc
3 May 24
Biofrontera Announces Achievement of Two Milestones Associated with Series B-3 Convertible Preferred Stock Warrants
9:15am
to the coverage, reimbursement and pricing for procedures using the Company’s licensed products; the uncertainties inherent in the initiation and conduct
8-K
BFRI
Biofrontera Inc
3 May 24
Biofrontera Announces Achievement of Two Milestones Associated with Series B-3 Convertible Preferred Stock Warrants
9:15am
) at least 95% of the Company’s territory managers, medical science liaisons, and reimbursement employees are using the Company’s customer relationship
DEFR14A
BFRI
Biofrontera Inc
30 Apr 24
Revised proxy
4:35pm
be within the sole discretion of the Company.
(d) With regard to any provision herein that provides for reimbursement of costs and expenses or in-kind … benefits, except as permitted by Section 409A of the Code, (i) the right to reimbursement or in-kind benefits shall not be subject to liquidation
8-K
EX-99.1
BFRI
Biofrontera Inc
26 Mar 24
Biofrontera Inc. Announces 2024 Annual Meeting of Stockholders and Deadlines for Submission of Stockholder Proposals
4:45pm
providers, including any changes to the coverage, reimbursement and pricing for procedures using the Company’s licensed products; the uncertainties
8-K
EX-99.1
wfn8saga2ivpw5
15 Mar 24
Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update
5:20pm
8-K
EX-99.1
nykdk2v4l706a
23 Feb 24
Biofrontera Inc. Announces Closing of Private Placement of Up To $16.0 Million priced at market per Nasdaq rules
9:26am
8-K
kqag zqe7tmdw6
23 Feb 24
Biofrontera Inc. Announces Closing of Private Placement of Up To $16.0 Million priced at market per Nasdaq rules
9:26am
8-K
EX-10.2
rbeny 79d82mhr
23 Feb 24
Biofrontera Inc. Announces Closing of Private Placement of Up To $16.0 Million priced at market per Nasdaq rules
9:26am
8-K
EX-4.1
3ivz58ul8c3tf8o05gm
23 Feb 24
Biofrontera Inc. Announces Closing of Private Placement of Up To $16.0 Million priced at market per Nasdaq rules
9:26am
8-K
EX-10.1
xhdqzkd9
20 Feb 24
Biofrontera Inc. Announces Restructuring of Supply Agreement with Biofrontera AG
9:37am
8-K
EX-99.1
d94eht7pi tjm5d
20 Feb 24
Biofrontera Inc. Announces Restructuring of Supply Agreement with Biofrontera AG
9:37am
8-K
EX-99.2
x7g4 c7n0gvpmx
20 Feb 24
Biofrontera Inc. Announces Restructuring of Supply Agreement with Biofrontera AG
9:37am
8-K
2e7z1uttpgoq48wvpj8
20 Feb 24
Biofrontera Inc. Announces Restructuring of Supply Agreement with Biofrontera AG
9:37am
8-K
EX-99.1
pvlhn7a m5cldpmjl
5 Feb 24
Biofrontera Inc. Announces FDA Filing of Supplemental New Drug Application for Ameluz® to Permit Up to Three Tubes per Use
5:25pm
8-K
EX-10.1
qtw8n
2 Feb 24
Entry into a Material Definitive Agreement
4:30pm